Kornimate/medical-research-clean huggingface dataset:
impact of etomidate vs. propofol on infectious complications post cardiac surgery

Conditions: Postoperative Complications

Summary: the aim of this retrospective before-after-study is to evaluate the potential association of etomidate vs. propofol as an induction agent for major cardiac surgery on infectious post-operative complications. the investigators hypothesize that etomidate increases the rate post-operative infectious complications in cardiosurgical patients.

etomidate had been a standard induction agent as it results in increased hemodynamic stability compared to propofol. this is seen as a major advantage in patients that frequently have a fragile haemodynamic situation. a major side effect of etomidate is the resulting adrenal dysfunction, which hampers the bodies stress response and has been shown to cause a higher mortality in infectious contexts such as sepsis. it remains unclear to what extend this attenuated stress response has an impact on the post-operative context in cardiosurgical patients. first preliminary data show that patients receiving etomidate as an induction agent are more prone to infection than those receiving a different agent, a definitive correlation is nevertheless still lacking. this is a retrospective before-after-study comparing the rate of infectious complications in patients receiving either valve and/or coronary cardiac surgery at the charité - universitätsmedizin berlin between october 1st, 2012 and january 31th, 2015. on october 1st, 2013 the standard operating procedures for anesthesia for cardiac surgery were amended and the induction agent at the charité - universitätsmedizin berlin was switched from etomidate to propofol. the investigators are therefore comparing patients undergoing cardiac surgery between october 1st, 2012 and september 30th, 2013 as the etomidate group with patients undergoing surgery between february 1st, 2014 and january 31st, 2015 as the propofol group. the gap in between the two groups (october 1st, 2013 - january 31st, 2014) was defined as a washout phase to account for a potential delay in implementation of the renewed standard operating procedures. patients will be investigated unmatched as well as matched according to (age, body mass index, american society of anesthesiologists physical status classification system (asa), new york heart association functional classification (nyha), surgical mode and diabetes). the data for both groups will be acquired from the 2 electronic patient data management systems at our hospital (copra system, sasbachwalden, germany, and sap, walldorf, germany).

Eligibility criteria:
inclusion criteria: * ≥ 18 years of age * valve and/or coronary artery bypass graft surgery exclusion criteria: * surgery during washout period (october 1st, 2013 - january 31st, 2014) * resurgery * endocarditis * known immunosuppression: * corticosteroid therapy * solid organ transplant * stem cell therapy * hiv diagnosis
simultaneous cochlear implantation during translabyrinthine resection of vestibular schwannoma

Conditions: Vestibular Schwannoma; Cochlear Implantation

Summary: this study will address the feasibility of simultaneous cochlear implantation during resection of a vestibular schwannoma.

this is prospective study patients undergoing a translabyrinthine resection for a vestibular schwannoma with intact hearing in the contralateral ear. during surgery, simultaneous cochlear implantation will be performed if the cochlear nerve can be identified and preserved during the resection. relevant data to be collected will include patient demographics, details related to the vestibular schwannoma including side, size, symptoms (specifically pre-operative hearing loss, degree of tinnitus), and status of hearing in the contralateral ear. surgical details to be recorded will include date of surgery, surgical time, and whether the cochlear nerve was identified and preserved. details related to the post-operative course to be recorded include length of stay in the hospital, post-operative complications such as wound infection or cerebral spinal fluid (csf) leak, and need for revision or additional procedures.

Eligibility criteria:
inclusion criteria: * patients with a vestibular schwannoma undergoing a translabyrinthine resection with intact hearing in the contralateral ear exclusion criteria: -
trial of excision versus photodynamic therapy in the treatment of bowen's disease

Conditions: Bowen's Disease

Summary: the purpose of this study is to identify the most optimal therapy for bowen's disease: excision versus photodynamic therapy.

the study is a randomized clinical trial in which two treatment options for bowen's disease, excision and photodynamic therapy, are compared on recurrence rate, cosmesis en expenses.

Eligibility criteria:
inclusion criteria: * age \> 18 years * histological proven bowen's disease on scalp, face, trunk, arms and legs * informed consent exclusion criteria: * recurrent bowen's disease * anogenital or subungual bowe's disease * other skin malignancy in the same area * porphyria

Keywords: treatment excision photodynamic therapy recurrence rate cosmetic outcome
beneficial effects of music on cognition and consciousness level

Conditions: Coma

Summary: exposure to music improves cognitive function in 'healthy' participants and in brain-damaged patients. however, it is still difficult to understand what precisely in music causes a positive effect : are they emotional components, familiarity or preference which improve cognition or is there any specific effect of music? moreover, it is not yet possible to characterize the neural and functional links between the brain systems solicited by music and those associated with other cognitive functions enhanced by music. finally, researches on brain-damaged patients have not exploited the potential effect of music on the level of alert and perceptual awareness, while this type of stimulation could be a valuable tool to improve cognition in patients with a disturbance of consciousness and alertness. the main objective is to describe the impact of music on the brain's response to self-referential or neutral stimuli in brain-damaged patients with persistent consciousness disorder after a coma and in healthy participants.


Eligibility criteria:
brain-damaged patients : inclusion criteria: * disorders of consciousness (traumatic brain injury, stroke or anoxic encephalopathy) * coma diagnosis (plum and posner, 1966), vegetative state (task force, 1994) or minimally conscious state (giacino, ashwal et al. 2002) * lack of autonomic crisis since one week minimum * medical condition considered stable * patients who do not present hearing loss. peaks i and ii of brainstem auditory evoked potentials (baep) will be normal. exclusion criteria: * hearing problem * uncontrolled epilepsy * autonomic crises * medical unstable state * pregnant or likely to be (interrogation data) or breastfeeding woman healthy participants : inclusion criteria: * subjects with normal hearing * absence of neurological disorder * subjects able to understand the experimental instructions exclusion criteria: * hearing problems and / or hearing loss higher than 30 decibels hearing level (db hl) at a frequency band from 250 to 8000 hz * neurological disorders * pregnant or likely to be (interrogation data) or breastfeeding woman

Keywords: brain-damaged disorders of consciousness post-coma consciousness coma vegetative state minimally conscious state music p300
effects of sitaglpitin on endothelial function during the ogtt in t2dm

Conditions: Type 2 Diabetes

Summary: to investigate whether single administration of sitaglitpin can restore acute endothelial dysfunction and ameliorate impaired increase of the number of endothelial progenitor cells (epcs) after oral glucose loading in patients with t2dm. to compare the effect of sitagliptin and glimepiride on endothelial function evaluated by flow-mediated vasodilatation (fmd) and the number of circulating epcs in patients with t2dm.

acute and chronic improvement of endothelial function is expected through the pleiotropic effect of dpp-4 inhibitors. a randomized, prospective, open-labeled, parallel design. the duration of treatments with sitagliptin or glimepiride is 12 weeks. the number of study centers is a single (dokkyo medical university hospital). participants will be randomized into the two treatment groups; (a) 50mg sitagliptin (n=15) and (b) 1mg glimepiride (n=15). anti-hyperglycemic effect is expected to be similar according to our study

Eligibility criteria:
inclusion criteria: * provision of informed consent before any study specific procedures * type ii diabetes who have inadequate glycaemic control (6.5%≦hba1c\<9.0%) * age from 20 to 80 years old * no history of using any antihyperglycemic drugs * no history of cardiovascular complications * no treatment or treatment with stable doses of lipid-lowering, antihypertensive, and antiplatelet agents for at least 3 months prior to randomization * 4.5 % ≤ fasting fmd at baseline \< 8.0 % exclusion criteria: * ・type i diabetes * pregnancy * liver disease (hepatic enzymes more than three times the upper limit of normal ranges) * impairared kidney function (serum crearinine greater than 1.3 mg/dl in men, 1.2 mg/dl in women) * cigarette smokers * contraindications to glimepiride and sitagliptin * active proliferative diabetic retinopathy
ds-5565 phase iii study for diabetic peripheral neuropathic pain

Conditions: Diabetic Peripheral Neuropathic Pain

Summary: investigate the efficacy and safety of ds-5565 in subjects with diabetic peripheral neuropathic pain (dpnp) in comparison to placebo

\[double blind phase\] the primary objective is to compare change in the average daily pain score(adps) from baseline to week 14 in asian subjects with dpnp receiving ds-5565 versus placebo. \[open extension phase\] the objective is to assess the long-term safety and efficacy of ds-5565 in subjects with dpnp.

Eligibility criteria:
inclusion criteria: * type 1 or type 2 diabetes mellitus at screening * painful distal symmetric polyneuropathy * at screening, a pain scale of ≥ 40 mm exclusion criteria: * hba1c (national glycohemoglobin standardization program) \> 10.0%

Keywords: diabetic peripheral neuropathic pain
should chronic stimulant medications be continued preoperatively in patients with attention deficit hyperactivity disorder(adhd)

Conditions: Attention Deficit Hyperactivity Disorder

Summary: patients on chronic stimulant therapy for the treatment of attention deficit hyperactivity disorder (adhd) who are undergoing an outpatient surgical or diagnostic procedure will be randomized to one of two groups: stimulant medication administered on the day of surgery or stimulant medication withheld on the day of surgery. the choice of anesthetic pharmacology will be at the discretion of the attending anesthesiologist, but the endpoint will be a bispectral index (bis) between 40 and 60 to ensure adequate and similar depth of anesthesia. blood pressure, heart rate and use of vasopressors or anticholinergics will be recorded and the incidence of hypotension, bradycardia, or administration of medications will be compared between the two groups.


Eligibility criteria:
inclusion criteria: * patients will be enrolled if they have been diagnosed with adhd and have been taking amphetamines and/or methylphenidate for at least the last six months and are undergoing an outpatient surgical or diagnostic procedure. exclusion criteria: * patients will be excluded if they are taking antidepressant medications, anxiolytic medication, analgesia medications other than acetaminophen or nsaids, if they have an allergy to midazolam, or a have cardiac disease. * procedures that entail the likelihood of blood transfusion will be excluded.
a safety study of 188-0551 spray versus reference listed drug (rld) in adult subjects with plaque psoriasis

Conditions: Plaque Psoriasis

Summary: adrenal suppression effects of corticosteroids are among the most important safety concerns for this group of products. this study is to determine and compare the adrenal suppression potential and the pharmacokinetic (pk) properties of 188-0551 spray versus an fda-approved drug (also known as a "reference listed drug" \[rld\]) under maximal use conditions when applied twice daily (approximately every 12 hours) in adult subjects with stable, moderate to severe, plaque psoriasis.


Eligibility criteria:
inclusion criteria: * subject is a male or non-pregnant female and is at least 18 years of age at the time of informed consent. * subject has provided written informed consent. * subject has moderate or severe psoriasis involving a minimum of 20% body surface area (bsa). * subject has an investigator's global assessment (iga) score of at least three (3 = moderate) at the baseline visit. exclusion criteria: * subject is pregnant, lactating, or is planning to become pregnant during the study. * subject has spontaneously improving or rapidly deteriorating plaque psoriasis. * subject has a physical condition which, in the investigator's opinion, might impair evaluation of plaque psoriasis, adrenal axis function or which exposes the subject to an unacceptable risk by study participation. * subject has had prolonged exposure to natural or artificial sources of ultraviolet radiation. * subject is currently enrolled in an investigational drug or device study. * subject has clinically significant abnormal labs at visit 1/screening that precludes topical steroid use, in the opinion of the investigator.
nasal intermittent positive-pressure ventilation for twin infants with respiratory distress syndrome

Conditions: Neonatal Respiratory Distress Syndrome

Summary: in the present study, we hypothesized that primary mode nippv initiated shortly after birth would decrease the incidence of intubation or death in twin infants when compared to ncpap.

after inclusion of eligible twins infants,one of the twins was supported by ncpap and another nippv.

Eligibility criteria:
inclusion criteria: * twins * clinical diagnosis of mild-moderate respiratory distress syndrome * requiring a fraction of inspired oxigen (fio2 ) \<0.40 to keep oxygen saturation of 90%-95% * a chest x-ray suggestive of early stage hyaline membrane disease, (i.e. mild microgranulia and air bronchogram) exclusion criteria: * pneumothorax * pneumomediastinum * surgical diseases * cardiac diseases * intraventricular hemorrage * major congenital defects

Keywords: nasal intermittent positive-pressure ventilation nasal continuous positive airway pressure twin respiratory distress syndrome
study on fluids associated to lung cancer

Conditions: Lung Cancer

Summary: the diagnosis of lung cancer is the first cause of cancer deaths for man and woman. it requires invasive procedures (at least endoscopy, transthoracic puncture, or surgery). this study is about the set up of an innovative test for lung cancer prognosis, based on biopsies and surgical material : lungcancertest, with the creation of a start-up in progress. the main goal of this study is to approve the diagnostic value of the molecular signature of the 26 genes (lungcancertest) revealed in blood and respiratory fluids among patients with lung cancer.


Eligibility criteria:
inclusion criterias : * patients with lung cancer in stage 1-2, lung cancer of all histology kind eligible for surgery (group 1). * patients with lung cancer in stage 3-4 (no adenocarcinoma or squamous) receiving classical or targeted chemotherapy on genetic anomalies (group 2). * control patients : carriers of non-cancerous radiological anomalies : benign nodules, cicatricial lesions, infectious or inflammatory, paired with the two other groups by age, sex or tobacco (group 3). * adults patients : over 18 years. * persons affiliated to national social security. * free signed consent. exclusion criterias : * persons referred to in articles l1121-5 to l1121-8 of csp ( protected people) : pregnants, parturients or breastfeeding women, person deprived of liberty by judicial or administrative decision, person under legal protection.

Keywords: cancer lung fluids lungcancertest radiological anomalies non-cancerous carriers patient reference
evaluation of potential effect of artemether - lumefantrine and malaria drugs on auditory function

Conditions: Malaria; Falciparum

Summary: to evaluate the potential effects of artemether- lumefantrine on the auditory function


Eligibility criteria:
inclusion criteria * 12 years of age or older * accepts healthy volunteers * p. falciparum parasitemia between 1,000 and 100,000 parasites/μl * history of fever or presence of fever (temperature ≥ 37.5°c) exclusion criteria * signs/symptoms of severe/complicated malaria * ingestion of various antimalarial drugs, or antibiotics in the previous 2 weeks to 2 months * history of any drug-related hearing impairment * abnormal hearing function at study entry * exposure to sustained loud noises, by self-report, within the past 24 hours * present ear problems * pregnant or lactating (urine test for β-hcg) to be performed on any woman of child bearing age) other protocol-defined inclusion/exclusion criteria may apply.

Keywords: malaria hearing co-artemether auditory plasmodium falciparum marsh fever plasmodium infections remittent fever paludism artemether artemisinins benflumetol lumefantrine
effects of attention training interventions on depression

Conditions: Depression; Attention Training; Symptoms, Cognitive; Symptoms, Affective; Symptoms, Behavioral

Summary: the purpose of this study is to study the effects of attention training interventions on symptoms and brain function in major depressive disorder.

attention training programs including mindfulness meditation-based interventions have been shown to be effective for treating depression. currently the biological and psychological mechanisms of action of attention training for major depression disorder are unknown. the objective of the current study is to improve the investigator's understanding of the mechanisms of attention training interventions for depression. research participants will include approximately 165 individuals with major depressive disorder randomized to one of three types of attention training programs. before and after intervention participants will complete a number of biological assessments including mri, eeg, behavioral tasks, and questionnaires. the study will be completed across three visits: (1) a screening visit; (2) data collection session 1; and (3) data collection session 2.

Eligibility criteria:
inclusion criteria include: * dsm-5 criteria for major depressive disorder * written informed consent * both biological sexes, any ethnicity * age 18-55 * scores exceeding cutoffs on depression questionnaires * right-handed * normal or corrected-to-normal vision and hearing * fluency in written and spoken english * absence of psychotropic medication exclusion criteria include: * use of substances or prior treatments that may interfere with study procedures or outcomes (e.g., stimulants, blood pressure medication) * medical conditions that may interfere with study procedures or outcomes (e.g., thyroid disorder) * current therapy and practices overlapping with study interventions * select other dsm-5 disorders and symptoms (e.g., psychotic symptoms, suicidal ideation) * failure to meet mri safety requirements or suitability * significant inconsistencies in self-report or first-degree relatives with history or current psychotic symptoms
tooth loss rate and its associated factors: a retrospective cross-sectional study with up to 50 years of follow-up.

Conditions: Tooth Loss

Summary: this study will evaluate, in an adult population (n=448) previously diagnosed with gingivitis and/ or periodontitis, the tooth loss rate and its potential associated factors such as diabetes, smoking, bruxism, cardiovascular diseases, and also the effect of supportive periodontal therapy on these factors, with an up to 50 years of follow-up period. significant results of the present study will help in the future reduction of tooth loss among periodontally involved patients.


Eligibility criteria:
inclusion criteria: * age \> 20 years. * patients diagnosed with generalized chronic periodontitis or gingivitis. * at least 10 years of follow-up after 1st visit. * all treatments and recall sessions were done by the same operator at the same specialized dental clinic. exclusion criteria: * patients with healthy periodontal status. * patients with orofacial anomalies and syndromes. * patients receiving periodontal treatments by different operators. * patients receiving periodontal treatments at different clinics. * patients receiving bisphosphonate therapy. * patients receiving chemotherapy or radiotherapy. * patients receiving a hormonal therapy. * patients with a history of refractory periodontitis or repeated abscess formation. * patients with debilitating diseases that could impair the immune system (hiv/aids, cancer, or autoimmune diseases).

Keywords: active therapy bruxism cardiovascular disease diabetes periodontitis smoking supportive periodontal therapy tooth loss tooth loss rate
study the novel functions and molecular mechanisms of vascular endothelial growth factor-c (vegf-c) in acute myeloid leukemia (aml)

Conditions: Acute Myeloid Leukemia

Summary: vascular endothelial growth factor (vegf)-c is recognized as a tumor lymphangiogenic factor based on the effects of activated vegfr3 on lymphatic endothelial cells. vegfr3 has been proposed as a specific marker for lymphatic endothelial cells. recent studies indicated that vegfr3 also expressed in a variety of human malignancies, including lung, colon rectal, or head and neck cancer. moreover, vegf-c/vegfr3 axis was demonstrated in regulating angiogenesis, cell invasion, and metastasis in several solid tumors. the promotion of cell mobility in response to vegf-c was required the involvement of adhesion molecule contactin-1. in addition to solid tumors, it has been reported that the vegf-c/vegfr3 axis is activated in subsets of leukemia patients. until now, it has been demonstrated that higher endogenous vegfc levels of acute myelogenous leukemia (aml) cells are related to decreased in vitro and in vivo responsiveness to chemotherapy; an effect that may result from inhibition of apoptosis by increasing bcl-2/bax ratios by the vegf-c/vegfr3 pathway. thus, a functional vegf-c/vegfr3 system may exist in leukemia. however, the detail information concerning the role of vegf-c/vegfr3 in non-solid tumors is still lacking. bone marrow neoangiogenesis plays a crucial pathogenic and possible prognostic role in aml. the vegf-c/vegfr3 axis has been proven in the regulation of solid tumors angiogenesis. in the investigators preliminary study, the investigators found vegf-c may play a critical role in angiogenesis regulation of leukemic cells by upregulating cyclooxygenase-2 (cox-2). furthermore, the investigators found that the upregulation of cox-2 also correlate with the vegf-c-induced proliferation in leukemic cells and this phenomenon might further regulate the chemoresistance of vegf-c. in this study, the investigators will investigate the extent of angiogenesis and chemoresistance induced by vegf-c in leukemic cells. this study will provide evidences on the subject of the novel role of vegf-c in leukemia. with progress in molecular biology of vegf-c, its value as a therapeutic target is highly promising.


Eligibility criteria:
inclusion criteria: * patients who were diagnosed acute myeloid leukemia exclusion criteria: * patients who were diagnosed other type leukemia

Keywords: we will collect the bone marrow specimens from aml patients